Zepbound on Dosley

Zepbound Tracker - log injections, weight, and side effects

Zepbound is a once-weekly injection of tirzepatide. This page explains how to track a Zepbound treatment with Dosley and links every medical fact to the FDA-approved label.

Dosley showing Zepbound pen details

Zepbound is the brand name for tirzepatide approved for chronic weight management in adults who meet the indication criteria, used alongside a reduced-calorie diet and increased physical activity. Because each treatment plan looks slightly different - different starting amounts, titration schedules, and side-effect timelines - keeping a personal log helps you and your prescriber see how things are going. Dosley is a private tracker for your injections, weight changes, and side-effect notes. It is not a medical device and does not give medical advice. The information below summarises the publicly available FDA-approved label so the page sits next to your tracker rather than inside it. If anything here differs from what your clinician has told you, follow your clinician.

At a glance

Active ingredient
Tirzepatide 1
Drug class
GIP and GLP-1 receptor agonist 1
Manufacturer
Eli Lilly and Company 2
FDA approval
November 2023 (NDA 217806) 3
Indication
Chronic weight management in adults who meet the BMI criteria, alongside diet and increased physical activity 1
Schedule
Once weekly, subcutaneous injection 1
Starting dose
2.5 mg once weekly 1
Maximum adult dose
15 mg once weekly 1
Missed-dose window
Within 4 days (96 hours) of the scheduled day 1
Storage
Refrigerated at 2–8°C; see the label for in-use room-temperature limits per pen format 1

Important safety information

Boxed warning

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Zepbound is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2. 1

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). 1
  • Known serious hypersensitivity to tirzepatide or any of the excipients in Zepbound. 1

Common side effects

  • Nausea ≈28% at 15 mg vs 8% placebo 1
  • Diarrhea ≈23% at 15 mg vs 8% placebo 1
  • Vomiting ≈13% at 15 mg vs 2% placebo 1
  • Constipation ≈11% at 15 mg vs 5% placebo 1
  • Abdominal pain ≈10% at 15 mg vs 5% placebo 1

Discuss benefits and risks with your healthcare provider before starting or continuing this medication.

Dosing and titration

Your prescriber decides every step on the schedule below. The summary here is for orientation while you log treatments - it is not a recommendation.

Treatment begins at 2.5 mg once weekly. After four weeks the prescriber may increase to 5 mg, then continue increasing in 2.5 mg increments after at least four weeks on the current dose, up to a maximum of 15 mg once weekly in adults. 1

The 2.5 mg starting amount is intended to help the body adjust before any maintenance amount is set. It is not the maintenance amount for most adults. 1

When you record a treatment in Dosley, you can attach the amount, the day, and any notes about how you tolerated it. The app does not change your schedule - it only records what your prescriber has set.

Injection sites and storage

Zepbound is given by subcutaneous injection in the abdomen, thigh, or upper arm. Rotating sites between treatments is recommended in the prescribing information. 1

Pens should be kept refrigerated between 2°C and 8°C until first use. Zepbound is supplied in single-dose pens and the multi-dose KwikPen; the room-temperature in-use period varies by pen format - follow the limit printed on your packaging or in the patient leaflet. 1

Tracking injection sites and storage windows in Dosley is optional but useful - it gives you a quick view of which sites you have used recently and when a pen needs to be retired or moved.

Zepbound and Mounjaro

Zepbound and Mounjaro contain the same active ingredient. They are different brand names with different FDA-approved indications.

Tirzepatide is sold as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes in adults who meet the indication criteria. Each brand has its own FDA-approved labeling, packaging, and patient leaflet. 1 3

Whether you have been prescribed one or the other is a question for your clinician. Dosley supports tracking either brand and treats them as separate treatments.

Missed dose

If a Zepbound injection is missed, the FDA label allows it to be taken as soon as possible within 4 days (96 hours) of the scheduled day. After that window, skip the missed amount and resume on the next regular day. 1

Questions

About this medication and Dosley

How often is Zepbound injected?

Zepbound is a once-weekly subcutaneous injection. Your prescriber sets the day of the week and the amount; Dosley records what they have set so you can see your history. 1

What if I forget my Zepbound on the scheduled day?

The FDA-approved label states the missed amount may be taken within 4 days (96 hours) of the scheduled day. After that window the missed amount is skipped and you wait until the next regular day. If you are unsure, contact your clinician. 1

What are the most common Zepbound side effects?

In the FDA label's adverse-reaction tables, the most common side effects at the 15 mg amount were nausea (about 28%), diarrhea (about 23%), vomiting (about 13%), constipation (about 11%), and abdominal pain (about 10%). Logging side effects in Dosley helps you and your prescriber spot patterns. 1

Is Zepbound the same molecule as Mounjaro?

Yes. Both Zepbound and Mounjaro contain tirzepatide, but each has its own FDA approval and indication: Zepbound is approved for chronic weight management and Mounjaro is approved for type 2 diabetes. Speak to your clinician about which is appropriate for your situation. 3

What does the SURMOUNT-1 trial say about weight change?

The FDA label reports that in SURMOUNT-1, mean weight reduction from baseline at week 72 was about 15.0% at the 5 mg amount, 19.5% at the 10 mg amount, and 20.9% at the 15 mg amount, compared with about 3.1% on placebo. Trial averages are not predictions for any individual. 1

Where is Zepbound injected?

The label specifies subcutaneous injection in the abdomen, thigh, or upper arm, with site rotation. Dosley lets you tag the site for each entry so you can see at a glance where you have already injected. 1

How should Zepbound be stored?

The FDA label says Zepbound should be kept refrigerated between 2°C and 8°C until first use. The in-use room-temperature window depends on the pen format you have been dispensed - check the leaflet that came with your pen. 1

Does Dosley send my Zepbound data to my clinic?

No. Dosley is a personal tracker. Your treatment log lives in your Dosley account, and you choose whether to export it as a PDF to share with your clinician. Talk to your healthcare team before changing anything in your treatment. 1

On Dosley

How Dosley supports a Zepbound routine

Dosley is built for the small rituals of a once-weekly injection routine. The home screen shows your next scheduled day so you never have to count from the calendar, and a quick log entry takes about five seconds - pick the day, the amount you were prescribed, the site, and you are done.

Side-effect notes live next to each entry. Many people find that the early weeks of a new amount bring temporary changes in how they feel; logging those alongside the entry helps you and your prescriber see whether things are settling or whether the schedule needs adjusting.

Weight is tracked in the same place. Manual entry is two taps; a chart shows the trend rather than the daily noise, so a single bad-scale day does not break your week. If you use Apple Health, weight syncs automatically.

Pen tracking helps with the practical side. Dosley remembers which pen is open and how many uses are left, so you know when to fetch a new one from the fridge. Storage windows are reminders, not rules - always follow the leaflet that came with your medication.

Everything stays on your device unless you choose otherwise. There is no clinic dashboard, no advertiser, and no requirement to create an account. If your healthcare team asks for a summary, you can export a PDF from the app and share it on your terms.

Track your treatment with Dosley

Log injections, weights, and side effects in a private space designed for GLP-1 routines.

App Store Google Play

References

  1. 1. FDA-approved Zepbound (tirzepatide) prescribing information (DailyMed)
  2. 2. Zepbound USPI (Eli Lilly and Company)
  3. 3. Drugs@FDA: Zepbound (NDA 217806)

Last reviewed:

Zepbound is a registered trademark of Eli Lilly and Company. Dosley is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.